The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice

Abstract To study the impact of dose modification and temporary interruption of ibrutinib in routine clinical practice, we conducted a retrospective study of consecutive CLL patients treated with ibrutinib outside the context of a clinical trial at Mayo Clinic, (Rochester, MN) from 11/2013 to 12/201...

Full description

Bibliographic Details
Main Authors: Sameer A. Parikh, Sara J. Achenbach, Timothy G. Call, Kari G. Rabe, Wei Ding, Jose F. Leis, Saad S. Kenderian, Asher A. Chanan‐Khan, Amber B. Koehler, Susan M. Schwager, Eli Muchtar, Amie L. Fonder, Kristen B. McCullough, Adrienne N. Nedved, Matthew D. Smith, Susan L. Slager, Neil E. Kay, Heidi D. Finnes, Tait D. Shanafelt
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:Cancer Medicine
Online Access:https://doi.org/10.1002/cam4.2998

Internet

https://doi.org/10.1002/cam4.2998

Similar Items